Will the FDA approve any psychedelic substance for medical use this year?
3.0 pts (24h)Health & MedicineOne-Off3mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Non 71%
Qualité du marché
64 / 100
Qualité moyenneVolume 24h
62,6 €
Liquidité
77 k €
Liquidité élevéeAchat / Vente
29.0% / 33.0%
Écart
4.0 pt
Spread modéréDonnées du marché
Mis à jour il y a 2 minutes
17 juil. 25, 14:00 UTC1 janv. 27, 04:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiRègles
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
- Important information: For purposes of this Contract:
- The listed substances are illustrative, not exhaustive.
- Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
- "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- 15,6 M €
- Volume 24h
- 20,4 k €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume total
- 919 k €
- Volume 24h
- 4,2 k €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 résultats de plus
- Volume total
- 2,6 k €
- Volume 24h
- 2,6 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 résultats de plus
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+3.0pt61%
+2 résultats de plus
- Volume total
- 866,7 k €
- Volume 24h
- 1,7 k €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- 611,8 k €
- Volume 24h
- 1,1 k €
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Will the FDA approve any psychedelic substance for medical use this year? ?
- Kalshi cote No à 71% au 10 septembre 2026.
- Quand Will the FDA approve any psychedelic substance for medical use this year? sera-t-il résolu ?
- Will the FDA approve any psychedelic substance for medical use this year? doit être résolu le 1 janvier 2027.
- Comment Will the FDA approve any psychedelic substance for medical use this year? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.